89% of Psoriasis Patients on J&J Pill Report Clear Genital Skin at Two Years
Two-year data for J&J's oral psoriasis therapy show 89% of patients achieved clear skin in previously affected genital areas, addressing a key evidence gap.
Topic
Johnson Johnson
Topic
Johnson Johnson
Icotrokinra Sustains High-Impact Site Clearance at 2 Years
Two-year ICONIC-TOTAL extension data show icotrokinra sustains clearance of high-impact psoriasis sites — scalp, face, palms, sol…
J&J Reports Two-Year Icotrokinra Durability Data in Plaque Psoriasis
J&J reports two-year icotrokinra durability data in difficult-to-treat plaque psoriasis, positioning the oral agent as a first-li…
FDA Approves J&J's Icotyde for Plaque Psoriasis
The US FDA has approved Johnson & Johnson's Icotyde for plaque psoriasis, adding a new systemic option for dermatologists in a cr…